Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Registrational; Therapeutic Use
- Acronyms PREVENT
- Sponsors Alexion AstraZeneca Rare Disease
- 18 Oct 2023 According to an AstraZeneca media release, Soliris (eculizumab) has been approved by the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).
- 13 Oct 2023 Results of post-hoc analysis assessing safety outcomes in patients who initiated C5IT treatment within 1 year of last rituximab exposure in the PREVENT and CHAMPION-NMOSD studies, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
- 11 Oct 2023 According to an AstraZeneca media release, company will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS), taking place 11 to 13 October 2023.